BCL B Cell Lymphoma Inhibitors Market to see Rapid Growth by 2029
BCL B cell lymphoma inhibitors market is anticipated to grow at a significant CAGR during the forecast period. BCL-2, also known as B Cell Lymphoma 2, is a protein-encoding gene belonging to the B cell lymphoma family. The market growth is majorly attributable to the growth in the prevalence of diffuse B cell lymphoma, a common type of non-Hodgkin lymphoma. For instance, according to an article by Lymphoma Research Foundation in 2019, in the US, DLBCL accounted for 22% of newly diagnosed B cell lymphoma cases. Around 18,000 people globally are diagnosed with DLBCL each year.
Adding to this, the disease
affects people over 60 years of age. According to the American Cancer Society
in 2019, an estimated 20,720 people were diagnosed with chronic lymphocytic
lymphoma. Moreover, 90% of the people diagnosed with this form of lymphoma are
estimated to affect people above 50 years of age. In the US, 2,220 men and
1,710 women are expected to be suffering from chronic lymphocytic lymphoma
every year. Moreover, as per the American Cancer Society, about 3,930
mortalities were anticipated to take place in 2019.
Further, there are various inhibitor drugs being
approved in the market that spur market growth. For instance, Venetoclax is the
only and first approved FDA BCL-2 inhibitor drug for chronic lymphocytic
lymphoma patients. Although various clinical trials are being carried out for
the development of new BCL-2 inhibitors.
Some key players operating in the market include
AbbVie, Roche, Abcam, Biorbyt, Biovison, and Tocris Bioscience. These players
are eyeing on strengthening their position in the market by adopting various
strategies as mergers and acquisitions, partnerships, collaborations, new
product launch and development in the existing product portfolio, and so on.
To Request a Sample of our Report on BCL B Cell Lymphoma
Inhibitors Market: https://www.omrglobal.com/request-sample/bcl-b-cell-lymphoma-inhibitors-market
Market Coverage
·
The market number available for – 2022-2030
·
Base year- 2022
·
Forecast period- 2023-2030
·
Segment Covered
·
Regions Covered- Globally
Competitive Landscape: AbbVie, Roche, Abcam, Biorbyt, Biovison, and
Tocris Bioscience
A
full Report of BCL B Cell Lymphoma Inhibitors Market is Available
at: https://www.omrglobal.com/industry-reports/bcl-b-cell-lymphoma-inhibitors-market
BCL B Cell Lymphoma Inhibitors Market - Segmentation
By Therapy
• Monotherapy
• Combination Therapy
By Type
• Positive Lymphoma
• Follicular Lymphoma
BCL B Cell Lymphoma Inhibitors Market Segmentation by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and
consulting company known for its crisp and concise reports. The company is
equipped with an experienced team of analysts and consultants. OMR offers
quality syndicated research reports, customized research reports, consulting
and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and
Consulting Services through another subsidiary Encanto Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment